rna_therapeutics

San Diego – October 29, 2026 -- Atrium Therapeutics (Nasdaq: RNA) has dosed the first patient in Corventis, a Phase 1/2 trial of ATR 1072 in PRKAG2 syndrome, and expects initial proof-of-concept data in the second half of 2027.

Corventis will enroll about 37 participants in two parts

The open-label, multicenter study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of ATR 1072. Part A uses multiple ascending dose cohorts to characterize safety and support dose selection. Part B is a single-arm expansion cohort at the recommended Phase 2 dose, assessing efficacy trends in cardiac structure and function.

The primary endpoint is the incidence of treatment-emergent adverse events. Secondary and exploratory endpoints include PRKAG2 mRNA reduction, siRNA tissue concentrations and plasma pharmacokinetics.

Seongnam, South Korea – September 10, 2026 -- Rznomics Inc. (KOSDAQ: 476830) has achieved up to a seven-fold increase in circular RNA (circRNA) production efficiency through engineering upgrades to its proprietary Self-Targeting and Splicing (STS) platform, according to peer-reviewed research published in Nucleic Acids Research on September 10, 2026.

Optimized STS method doubles circularization efficiency versus industry-standard PIE technique

In tests using Factor VIII RNA measuring approximately 7.8 kilo-nucleotides in length, the upgraded STS approach delivered roughly twice the circularization efficiency of the widely used Permuted Intron–Exon (PIE) method, a standard benchmark in circRNA manufacturing. The finding directly addresses a persistent industry constraint: circularization efficiency typically drops as RNA length increases, limiting the size of genes that can be produced at commercial scale.